<DOC>
	<DOCNO>NCT00494442</DOCNO>
	<brief_summary>The purpose study see drug KU 0059436 effective well tolerate treat patient measurable BRCA1- BRCA2-positive advanced ovarian cancer curative therapeutic option exists .</brief_summary>
	<brief_title>Study Assess Efficacy Safety PARP Inhibitor Treatment BRCA-positive Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Advanced ovarian cancer positive BRCA1 BRCA2 status Failed least one prior chemotherapy In investigator opinion , curative standard therapy exist Measurable disease Brain metastases Less 28 day since last treatment use treat disease Considered poor medical risk due serious uncontrolled disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced ovarian cancer</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>KU-0059436</keyword>
	<keyword>AZD2281</keyword>
	<keyword>BRCA1 protein</keyword>
	<keyword>BRCA2 protein</keyword>
</DOC>